The approval makes Dupixent the first FDA-approved therapy for allergic fungal rhinosinusitis, supported by Phase III data showing significant improvements in sinus opacification, nasal symptoms, and ...
Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and ...
TARRYTOWN, N.Y. and PARIS, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved ...
The FDA has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis.
People with allergic fungal rhinosinusitis taking Dupixent (dupilumab) saw significant improvement in congestion and sinus ...
Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitisApproval in adults and ...
TORONTO, Oct. 22, 2025 /CNW/ - Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) ...
US FDA approves Sanofi and Regeneron’s Dupixent for allergic fungal rhinosinusitis: Paris Thursday, February 26, 2026, 15:00 Hrs [IST] The US Food and Drug Administration (FDA) ...
The FDA approved Dupixent as the first treatment for allergic fungal rhinosinusitis in adults and children over six years old ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results